Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer
Metrics: PDF 638 views | HTML 1269 views | ?
Aleksi Suo1, Allison Childers2, Adrijana D’Silva1, Lars F. Petersen2, Shannon Otsuka1, Michelle Dean2,3, Haocheng Li1,4, Emeka K. Enwere2,3, Brant Pohorelic3, Alexander Klimowicz3, Ivana A. Souza5, Jawed Hamid5, Gerald W. Zamponi5 and DGwyn Bebb1,2
1Department of Oncology, Tom Baker Cancer Centre, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
2Translational Laboratories, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
3Functional Tissue Imaging Unit, Translational Laboratory, Tom Baker Cancer Centre, Calgary, AB, Canada
4Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
5Department of Physiology and Pharmacology, Hotchkiss Brain Institute and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Aleksi Suo, email: firstname.lastname@example.org
Keywords: T-type VGCC; Cav3.1; NSCLC
Received: April 04, 2017 Accepted: December 05, 2017 Published: January 12, 2018
Introduction: Voltage-gated calcium channels (VGCC) have been found to be differentially expressed in several different tumor types, but their role in tumor growth, malignant invasion, metastases and impact on clinical outcomes has not been clarified.
Materials and Methods: From a cohort database of 193 patients with early-stage NSCLC, 163 formalin-fixed paraffin-embedded specimens were available for analysis to construct tissue microarrays. Cav3.1 protein expression was detected using fluorescence immunohistochemistry, and quantified using automated image acquisition and analysis.
Results: Among the cohort of 193 NSCLC patients, adenocarcinoma (53.9%) and squamous cell carcinoma (SCC) (30.1%) were the most common histologies. There was no difference between SCC and non-SCC subtypes in overall survival (OS) or relapse-free survival (RFS); 74.2 vs 90.1 months (p = 0.543) and 48.8 vs 52.6 months (p = 0.766), respectively. T-type VGCC 3.1 (Cav3.1) overexpression was assessed by tissue microarray immunohistochemistry analysis from 163 available patient samples. Eighteen (11.0%) NSCLC primaries were found to have Cav3.1 overexpression levels, and were significantly associated with SCC histology (p < 0.001), larger tumor size (p < 0.001) and later stage disease at diagnosis (p = 0.019). Median OS was 48.6 vs 106.7 months for Cav3.1 overexpressing and non-overexpressing patients, respectively (p = 0.032). Regression analysis revealed a significantly negative effect for Cav3.1 overexpression on RFS (Hazard ratio [HR] = 2.02, p = 0.048).
Conclusions: Cav3.1 overexpression is a potential biomarker for poorer patient outcomes. These results bring supportive evidence for calcium channels inducing an aggressive phenotype in NSCLC and potentially may serve as a therapeutic target in overexpressing tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.